Previous 10 | Next 10 |
2024-02-13 12:37:03 ET Incyte Corporation (INCY) Q4 2023 Earnings Conference Call February 13, 2024, 08:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Hervé Hoppenot - Chief Executive Officer Barry Flannelly - General...
2024-02-13 07:10:06 ET Incyte press release ( NASDAQ: INCY ): Q4 Non-GAAP EPS of $1.06 misses by $0.09 . Revenue of $1.01B (+9.0% Y/Y) beats by $10M . 2024 Financial Guidance ... Read the full article on Seeking Alpha For further details s...
Total FY'23 net product and royalty revenues of $3.7 billion (+14% Y/Y); total FY'23 net product revenues of $3.2 billion (+15% Y/Y) Jakafi ® (ruxolitinib) net revenues of $2.6 billion (+8%) for FY'23; Jakafi net revenues guidance range of $2,690 - $2,750 million for FY 2024 ...
ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...
2024-02-12 11:41:12 ET More on Incyte Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab Incyte buys global rights for tafasitamab from MorphoSys Agilent, Incyte to collaborate on companion diagnostics development Seeking Alpha...
2024-02-07 08:55:30 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – February 7, 2024 – USA News Group – One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer ...
2024-02-05 17:52:08 ET More on Incyte Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab Agilent, Incyte to collaborate on companion diagnostics development Why did Incyte stock go up today? Positive drug study Seeking Alpha ...
2024-02-05 17:02:22 ET Novartis ( NYSE: NVS ) said it will acquire cancer drugmake r MorphoSys AG ( MOR ) for EUR 68/share, or an aggregate of EUR 2.7B.... Read the full article on Seeking Alpha For further details see: Novartis to buy cancer drugmaker Mo...
– Tafasitamab is approved in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and is currently in Phase 3 trials for multiple indications Incyte (Nasdaq:INCY) announced it has entered into an asset purchase agreeme...
2024-02-05 10:24:24 ET More on MorphoSys MorphoSys: Positive Pelabresib Data Finally Unlocking Upside MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis MorphoSys: Buying Constellation Was A Desperate Measure MorphoSys expects 20...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...